Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer.

CDR-404 is under clinical development by CDR-Life and currently in Phase I for Squamous Non-Small Cell Lung Cancer.

The early detection of cancer in patients in Sussex has risen to its highest ever level, according to new NHS analysis. Of ...

Researchers have discovered why the lungs are often targeted by metastasizing cancer cells, pinpointing the amino acid ...

New research reveals why cancer often spreads to the lungs, identifying elevated aspartate levels as a key factor in aiding ...

Much of our knowledge of the protein PD-1, a leading cancer treatment target, comes from studies in mice. In a comprehensive assessment of PD-1, researchers have found that PD-1 in mice is ...

The family of a retired Westchester school employee is reaching out to the community for help as they raise funds for a ...

Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...

By narrowing their research to overweight and obese individuals, Roswell Park researchers found that metformin might offer ...

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

From tennis star Gabriela Dabrowski sharing details of her breast cancer journey to Greg Gumbel and Linda Lavin dying, here ...